The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: This review focuses on the multi-ligand receptor of the immunoglobulin superfamily--receptor for advanced glycation endproducts (RAGE). The accumulation of the multiple ligands of RAGE in cellular stress milieux links RAGE to the pathobiology of chronic disease and natural aging. AREAS COVERED: In this review, we present a discussion on the ligands of RAGE and the implications of these ligand families in disease. We review the recent literature on the role of ligand-RAGE interaction in the consequences of natural aging; the macro- and microvascular complications of diabetes; obesity and insulin resistance; autoimmune disorders and chronic inflammation; and tumors and Alzheimer's disease. We discuss the mechanisms of RAGE signaling through its intracellular binding effector molecule--the formin DIAPH1. Physicochemical evidence of how the RAGE cytoplasmic domain binds to the FH1 (formin homology 1) domain of DIAPH1, and the consequences thereof, are also reviewed. EXPERT OPINION: We discuss the modalities of RAGE antagonism currently in preclinical and clinical studies. Finally, we present the rationale behind potentially targeting the RAGE cytoplasmic domain-DIAPH1 interaction as a logical strategy for therapeutic intervention in the pathological settings of chronic diseases and aging wherein RAGE ligands accumulate and signal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Self-citationBlockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Self-citationYONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“[113–117] The possibilities for therapeutic opportunities targeting RAGE in AD are mounting; in addition to agents being tested against RAGE in preclinical models,[120] a inhibitor of RAGE is in clinical trials after evidence of potential efficacy in prevention in cognitive decline in human subjects with AD.”
BackgroundRAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
Yamamoto, Y., Kato, I., Doi, T., Yonekura, H., Ohashi, S., Takeuchi, M., Watanabe, T., Yamagishi, S.-I., Sakurai, S., Takasawa, S., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11771 · Cited by 475
Lue, L.-F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., Stern, D. M., & Yan, S. D. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7732 · Cited by 439
Self-citationSoro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407 · cited 1×
“Genetic deletion of Ager in both diabetic models resulted in reduced atherosclerosis and, importantly, macrophage content per lesion area was lower – in parallel with increased lesional collagen, a marker of stability (Figure 1).[29,30] The ligands of RAGE also accumulate in non-diabetic atherosclerosis, but to a sign…”
BackgroundRage and arthritis: The G82S polymorphism amplifies the inflammatory response
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., Lalla, E., Chitnis, S., Monteiro, J., Stickland, M. H., et al. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363861 · Cited by 383 · cited 4×
“In human subjects, a particular polymorphism of RAGE (“RAGEG82S”) was found to be in linkage disequilibrium with HLA-DR4, which is classically associated with rheumatoid arthritis.[64,65] Mice vulnerable to autoimmune bone and joint tissue destruction treated with sRAGE displayed significantly less joint inflammation…”
BackgroundSelf-citation
Cited by
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
Khosla, S., Samakkarnthai, P., Monroe, D. G., & Farr, J. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00555-5 · Cited by 260
MacLean, M., Derk, J., Ruiz, H. H., Juranek, J. K., Ramasamy, R., & Schmidt, A. M. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.012 · Cited by 69
Self-citationRAGE Signaling in Skeletal Biology
Plotkin, L. I., Essex, A. L., & Davis, H. M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00499-w · Cited by 54
Metadata
- Authors
- Ramasamy, R., Shekhtman, A., & Schmidt, A. M.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2015-11-11
- Volume
- 20
- Issue
- 4
- Pages
- 431-446
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2180139331
- Cited by
- 109
- References
- 22
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease. https://app.cochat.ai/papers/10.1517/14728222.2016.1111873
- The paper
- Ramasamy, R., Shekhtman, A., & Schmidt, A. M. (2016). The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2016.1111873
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.